1527 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Recruiting Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Condition: Non Small Cell Lung Cancer
Interventions: Procedure: Stereostatic Radiosurgery;   Drug: Erlotinib
22 Recruiting INHERIT EGFR - Studying Germline EGFR Mutations
Condition: Lung Cancer
Intervention:
23 Active, not recruiting A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
Condition: Non Small Cell Lung Cancer
Intervention:
24 Not yet recruiting C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
Conditions: Lung Cancer;   Pancreatic Cancer
Intervention: Other: C11-Erlotinib PET/CT
25 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention:
26 Completed Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
Condition: Solid Tumor
Interventions: Drug: enzyme inhibitor therapy;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
27 Recruiting Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
28 Recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
29 Active, not recruiting Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
30 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
31 Recruiting Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Condition: Stage IV Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Fulvestrant;   Drug: Erlotinib
32 Recruiting A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
33 Not yet recruiting Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CO-1686 Mono-Therapy;   Drug: Erlotinib Mono-Therapy
34 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
35 Recruiting A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment
Conditions: Non-small Cell Lung Cancer (NSCLC);;   EGFR-TKI Resistant Mutation;;   EGFR-TKI Sensitizing Mutation;;   Germline Mutations
Intervention:
36 Not yet recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
37 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Positive EGFR Mutation
Intervention: Drug: BIBW 2992
38 Active, not recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
39 Recruiting Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: combined group;   Drug: Sequenced group
40 Recruiting Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor
Condition: Non-Small-Cell Lung Cancer
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years